Loading
RSPO3 (R-spondin-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Breast cancer and Lung cancer. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Activator of the canonical Wnt signalling pathway by acting as a ligand for LGR4-6 receptors, which acts as a key regulator of angiogenesis. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signalling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signalling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway. Acts as a key regulator of angiogenesis by controlling vascular stability and pruning: acts by activating the non-canonical Wnt signalling pathway in endothelial cells. Location: Secreted (UniProt). Locus 6q22.33 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Colorectal cancer | 0.4-10% | Gene fusion (PTPRK-RSPO3, EIF3E-RSPO2) | Recurrent RSPO2 and RSPO3 fusions occurred together in 10% of more than 70 colon tumours analysed by exome, transcriptome and copy number, and were mutually exclusive with APC mutation (Seshagiri 2012; coadread_genentech). Targeted panels find far fewer because they bait the RSPO3 intron but not RSPO2: cBioPortal structural variants give PTPRK-RSPO3 in 32 of 7,237 samples, 0.44%, in crc_msk_2026 (RSPO2 3 samples) and RSPO3-PTPRK in 3 of 1,516 in crc_eo_2020. | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"RSPO3" OR ABSTRACT:"RSPO3" OR TITLE:"R-spondin 3" OR ABSTRACT:"R-spondin 3" OR TITLE:"R-spondin-3" OR ABSTRACT:"R-spondin-3" OR TITLE:"FLJ14440" OR ABSTRACT:"FLJ14440" OR TITLE:"THSD2" OR ABSTRACT:"THSD2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RSPO3, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/rspo3.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rspo3.json. Licence CC BY-NC 4.0.